| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Araloside A targets inflammatory pathways, specifically by decreasing the production of pro-inflammatory cytokines IL-1β and IL-6. It also targets the Fas/FasL pathway, which is involved in apoptosis. It has low renin-inhibitory activity. As a triterpenoid saponin, it may modulate membrane-associated signaling, inflammation, oxidative stress, apoptosis, and immune responses.
|
|---|---|
| ln Vitro |
In vitro, Araloside A increases apoptosis of human MH7A cells and decreases production of IL-1β and IL-6. It has low renin-inhibitory activity. Its anti-inflammatory and pro-apoptotic activities suggest potential applications in the treatment of inflammatory and autoimmune diseases.
|
| ln Vivo |
In vivo, Araloside A has anti-inflammatory and gastroprotective effects. It is expected to relieve cutaneous symptoms caused by excessive apoptotic cell death in the skin through the Fas/FasL pathway. Its ability to reduce oxidative stress has also been reported. Further in vivo studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro assays for Araloside A are conducted to evaluate its anti-inflammatory and pro-apoptotic activities. Human MH7A cells are treated with compound concentrations ranging from 0.1 to 100 µM. Cytokine levels (IL-1β, IL-6) are measured by ELISA. Apoptosis is assessed by flow cytometry using Annexin V/PI staining or by measuring caspase activity. Renin inhibition assays are performed using purified renin enzyme.
|
| Cell Assay |
Cellular assays for Araloside A are performed using human MH7A cells or other cell lines. Cells are treated with compound concentrations ranging from 0.1 to 100 µM for 24-72 hours. Cell viability is assessed using MTT or CCK-8 assays. Apoptosis is evaluated by flow cytometry. Cytokine production is measured by ELISA.
|
| Animal Protocol |
In vivo animal studies for Araloside A would typically utilize rodent models of inflammation, gastric ulcer, or autoimmune disease. The compound is administered orally or intraperitoneally. Endpoints include inflammatory markers, gastric lesion index, and histopathological evaluation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Araloside A are not well characterized. The compound has a molecular weight of 927.08 and a molecular formula of C₄₇H₇₄O₁₈. As a triterpenoid saponin, it is expected to have limited oral bioavailability due to poor membrane permeability and extensive first-pass metabolism. Standard PK studies in rodents would be required.
|
| Toxicity/Toxicokinetics |
Toxicological data for Araloside A are limited. As a natural product-derived compound, it may have a moderate safety profile. No significant acute toxicity has been reported. The compound is designated for research use only.
|
| References | |
| Additional Infomation |
Bamboo saponin IV is a triterpenoid saponin that acts as a metabolite. Aralloside A has been reported to be found in Caragana sinica, ginseng, and other organisms with relevant data.
Araloside A is a triterpenoid saponin with anti-inflammatory and gastroprotective effects. It increases apoptosis and decreases IL-1β and IL-6 production in MH7A cells. It has a molecular weight of 927.08 and formula C₄₇H₇₄O₁₈. It is not clinically approved. |
| Molecular Formula |
C₄₇H₇₄O₁₈
|
|---|---|
| Molecular Weight |
927.08
|
| Exact Mass |
926.487
|
| CAS # |
7518-22-1
|
| PubChem CID |
10079497
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
999.1±65.0 °C at 760 mmHg
|
| Melting Point |
196-200℃
|
| Flash Point |
285.6±27.8 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.623
|
| LogP |
7.54
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
65
|
| Complexity |
1830
|
| Defined Atom Stereocenter Count |
22
|
| SMILES |
C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)(C)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O[C@H]8[C@@H]([C@H]([C@@H](O8)CO)O)O)O)O
|
| InChi Key |
KQSFNXMDCOFFGW-GNDIVNLPSA-N
|
| InChi Code |
InChI=1S/C47H74O18/c1-42(2)14-16-47(41(59)65-39-33(55)30(52)28(50)23(19-48)61-39)17-15-45(6)21(22(47)18-42)8-9-26-44(5)12-11-27(43(3,4)25(44)10-13-46(26,45)7)62-40-34(56)31(53)35(36(64-40)37(57)58)63-38-32(54)29(51)24(20-49)60-38/h8,22-36,38-40,48-56H,9-20H2,1-7H3,(H,57,58)/t22-,23+,24-,25-,26+,27-,28+,29-,30-,31+,32+,33+,34+,35-,36-,38-,39-,40+,44-,45+,46+,47-/m0/s1
|
| Chemical Name |
(2S,3S,4R,5R,6R)-6-[[(3S,4aR,6aR,6bS,8aS,12aS,14aR,14bR)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3-[(2S,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxyoxane-2-carboxylic acid
|
| Synonyms |
Chikusetsusaponin IVAraloside A
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~107.87 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (1.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (1.35 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (1.35 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0787 mL | 5.3933 mL | 10.7866 mL | |
| 5 mM | 0.2157 mL | 1.0787 mL | 2.1573 mL | |
| 10 mM | 0.1079 mL | 0.5393 mL | 1.0787 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
